

PreMD Inc.  
Form 6-K  
February 01, 2006

---

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE  
SECURITIES EXCHANGE ACT OF 1934

Dated February 1, 2006

**PreMD Inc.**

---

Commission File Number 1-31360

615-4211 Yonge Street  
Toronto, Ontario M2P 2A9  
CANADA

---

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Edgar Filing: PreMD Inc. - Form 6-K

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

**PreMD Inc.**

Form 6-K

**On February 1, 2006**, the Corporation issued a news release announcing that Dr. Michael Evelegh, Executive Vice President, Clinical and Regulatory Affairs, has been invited to make an oral presentation on the company's cancer tests at a symposium titled *Tumor Markers for Personalized Medicine: The New Frontier*, sponsored by The University of Texas M.D. Anderson Cancer Center, March 5 - 9, 2006. The information contained in the news release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

PreMD Inc.

By:

/s/ Ronald G. Hosking

Ronald G. Hosking

Vice President and Chief Financial Officer

Date: February 1, 2006

---

EXHIBIT INDEX

Exhibit Number	Description
99.1	The Registrant's News Release Dated February 1, 2006